RJ Hamster
RJ Hamster
RJ Hamster
RJ Hamster
Exercise Is Better Than Antidepressants
Breaking News from Newsmax.com
Exercise Is Better Than Antidepressants
Dr. David Brownstein, M.D., writes:
Antidepressant medications such as Prozac and Zoloft are prescribed far too often. The mechanism of action of this class of medications has not been fully explained.
When they first came to market, these drugs were touted as the cure for a chemical imbalance in the central nervous system. Research has disproved that claim.
Special: Dr. Crandall Saved His Own Heart With This
Antidepressants are associated with nutrient deficiencies such as CoQ10, magnesium, melatonin, and vitamins D, B6, and B12.
Studies have shown that daily exercise is equal or superior to antidepressants for those suffering from mild to moderate depression. Eating a healthy diet usually helps a patient suffering from depression.
Before going on an antidepressant medication, I suggest exercising daily, eating a healthy diet, and correcting hormonal and nutritional imbalances.
Americans take more prescription medications than any other people on the planet. Do we have better health from taking so many drugs? Absolutely not. We come in last or next to last in nearly every health indicator.
There is a time and a place for pharmaceuticals. However, there is also a time and place for educating yourself about a healthy, holistic lifestyle. Adopting such a lifestyle can minimize the chance of needing a pharmaceutical product that poisons enzymes and blocks receptors in the body, which nearly all drugs do. It’s best to work with a holistic physician who is trained in both pharmacology and natural therapies.
Dr. David Brownstein, M.D., editor of the Natural Way to Health newsletter, is a board-certified family physician and one of the nation’s foremost practitioners of holistic medicine. In addition to his practice, Dr. Brownstein has lectured internationally to physicians and is the author of more than a dozen very popular books.
More Links:
Warren Buffett Bets $71 Billion on AI Investments… Read More Here
The #1 Underlying Cause of Today’s Deadliest Diseases
Many people have heard of coenzyme Q10 (CoQ10), but don’t really understand the crucial role it plays in health.
CoQ10 is a natural, vitamin-like substance found in body cells, particularly in organs with higher energy needs — like the heart.
All cells contain mitochondria, microscopic “powerhouses” that generate life-giving energy. CoQ10 plays a vital part in this energy production process.
In addition to enhancing cellular energy production in the heart, brain, and other organs, CoQ10 provides additional benefits. During energy production, cell-damaging free radicals are formed as byproducts of this oxidation process. And as a powerful antioxidant, CoQ10 helps counteract this oxidative stress, further supporting the health of cells in the heart and other organs.
Research also indicates that CoQ10 helps promote the health of the endothelium, or inner lining of blood vessels. This is important to cardiovascular health because it supports normal circulation and balanced inflammation.
Aging Adults & Statin Users Need More CoQ10
Unfortunately, CoQ10 levels decrease with age. In fact, CoQ10 levels are highest in the first 20 years of life, but decline gradually after that point. By the fourth decade, CoQ10 levels may have dropped as much as 30%.
Statin drugs used for cholesterol also deplete natural levels of CoQ10. Because of these issues, renowned cardiologist Dr. Chauncey Crandall decided to work with experts at the premium supplement company Medix Select to develop the advanced formula COTREXIN® with CoQ10.
Why Most CoQ10 Is a Waste of Money
Many traditional CoQ10 supplements provide less than 200 mg a day of CoQ10, so they are unlikely to deliver significant cardiac benefits. In addition, typical CoQ10 is very poorly absorbed by the body.
The reason most CoQ10 is poorly absorbed is because it is insoluble in water and soluble in oil. With the body being up to 60% water, most of the CoQ10 doesn’t dissolve and is excreted in the urine — literally flushed away.
That’s why Dr. Crandall added BioPerine® black pepper fruit extract to COTREXIN. This patented nutrient increases absorption levels and bioavailability by up to 30%.
And unlike many typical supplements, COTREXIN offers a full 200 mg of CoQ10 per daily serving of two capsules. But Dr. Crandall didn’t stop there. He added another ingredient to the COTREXIN formula.
COTREXIN Includes Omega-3s for Added Cardio Support
COTREXIN contains 850 mg of omega-3s per daily serving, with 650 mg of EPA and 100 mg of DHA.
Scientific research has shown that omega-3s found in fish oil, including EPA and DHA, promote heart health and normal cholesterol. Omega-3s also promote normal inflammatory balance. In addition, DHA supports brain health.
The Dynamic Duo for Powerful Heart Health Support
COTREXIN with CoQ10 and omega-3s makes it easy to help support the entire cardiovascular system. Try COTREXIN today!
Get Your RISK-FREE Trial Bottle of Heart-Healthy COTREXIN Today
We at Medix Select, one of the nation’s premier nutraceutical companies, are sure you’ll love COTREXIN, too. That’s why we’re offering a risk-free 30-day trial supply at NO COST. That’s a $39.95 value! Just cover a small shipping fee of $4.95, that’s all.
9 Health Benefits of Doctor-Developed COTREXIN®
- Supports Heart Health and Function
- Supports Brain Health
- Enhances Cellular Energy Production
- Supports Normal Blood Pressure Levels
- Supports Circulatory Health
- Promotes Healthy Inflammatory Response
- Supports Antioxidant Activity
- Supports Healthy Triglyceride Levels
- Helps Reduce the Oxidation of Cholesterol
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Trial requires enrollment in the SmartShip program, terms and conditions apply. Please call or view our website for complete details. All information presented above is for informational purposes only, and is not specifically applicable to any individual’s medical problem(s), concerns, and/or needs. Readers are advised to consult a health professional about any issue regarding their health and well-being. ©2026 Medix Health LLC. All rights reserved. Medix Select is a registered trademark of Medix Health LLC.
This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
Remove your email address from our list or modify your profile. We respect your right to privacy. View our policy.
This email was sent by:
Newsmax.com
362 N. Haverhill Road
West Palm Beach, FL 33415 USA
DM945886
010102zdo9if
RJ Hamster
RJ Hamster
Daily Movers: TD Cuts Bitcoin Giant Strategy’s Price Target,…
Your recap for April 9, 2026 Top stories for youTD Cuts Bitcoin Giant Strategy’s Price Target, Calls Ethereum Treasury Sharplink a ‘Buy’Oil Rises in Choppy Session as Saudi Supplies Hit By AttacksVista Investment Partners Just Bought a New $4.7 Million Stake in Federated HermesThe Best Reason to Buy ExxonMobil Right Now Isn’t High Oil PricesWhy Walmart’s CFO Says American Consumers Are More ‘Resilient’ Than It May SeemView more storiesMy portfolio highlightsDay Change +1.22%Top gainersKBLBKraig Biocraft La…0.14
+6.15%CROXCrocs101.95
+5.02%UURAFUcore Rare Metals4.13
+4.82%Top losersLOGILogitech91.06
-3.94%JKHYJack Henry & …153.38
-2.91%SJMThe J. M. Smucker…92.47
-1.41%Most activesXOMExxon Mobil155.04
-0.76%CSCOCisco Systems83.17
-0.63%MSTRStrategy Inc128.86
+0.44%View your portfoliosUS market highlightsS&P 500
+0.62%Dow 30
+0.58%Nasdaq
+0.83%Russell 2000
+0.6%Crude Oil
+4.62%Top gainersEOSE
Eos Energy Enterp…5.95
+29.63%YSS
York Space System…36.01
+28.84%AXTI
AXT Inc63.12
+18.69%Top losersTPL
Texas Pacific Lan…377.97
-15.68%QLYS
Qualys, Inc.76.68
-12.23%SNOW
Snowflake Inc.132.24
-11.83%Most activesINTC
Intel Corporation61.72
+4.7%HOLX
Hologic, Inc.76.01
+0.0%NVDA
NVIDIA Corporation183.91
+1.01%Yahoo Finance App: Portfolio performance, news and alerts, stock data and all you need in a finance app. Download now.
Privacy Policy | Customer Support | Unsubscribe
©2026 Yahoo Inc. All Rights Reserved.
770 Broadway, New York, NY 10003
RJ Hamster
sun devil baseball – Google Search
sun devil baseball – Google Search
— Read on www.google.com/search
RJ Hamster
the RJ Hamster Show
RJ Hamster
Back to Bulls or Rug Pull?
Wednesday, April 8, 2026
You’re Watching the Wrong Stocks
Every morning you scan the same giants, Apple, Tesla, Nvidia, right alongside everyone else, and every week you watch the real movers rip in names you never had on your radar.
That’s not bad luck. That’s structural. Money rotates out of crowded tickers into neglected ones, and by the time the move is obvious, the easy gains are already gone.
Jeff Bierman’s BURN SIGNAL is built to catch that rotation early, the same clue that flagged NFLX +$14 in 4 days and CAT +$26 in 2 days before the breakouts looked obvious.
Tomorrow at 2pm EST, Jeff is going live and free to show you exactly what he watches for.
You’ll discover how he can spot these rotations before everyone else and turn them into actionable trades.
👉 [CLICK HERE TO RESERVE YOUR SEAT]
Don here…
The S&P 500 just ripped 2.4% to the upside. Everyone’s celebrating. The VVIX says they shouldn’t be.
The VVIX is the volatility of the VIX itself. It measures what professional traders are actually doing with their hedges. On a day where the market exploded higher, the VVIX only dropped 5%.
That tells you something critical. The professional world is not giving up their protection.
VIX options traded nearly 1.6 million contracts today. That is enormous volume for a day where the market supposedly just resolved its problems.
And here’s what most people are missing about this rally. We went from unchanged on the week to the upper edge of the weekly expected move. The $167 expected move landed almost to the penny. There is nothing unprecedented about where we are right now.
The real story is underneath the surface. I faded the financials today with a bearish position in XLF after we cracked through the expected move. Earnings kick off next week, and if this market fades from here, financials get hit hardest.
Tech told the real story today. In tonight’s video, I walk through the specific names flashing warning signs and the ones still showing strength:
- Tesla traded on massive volume and nearly cracked through its recent lows, closing at the lower edge of its expected move.
- Microsoft bounced early, hit the upper edge of its expected move, then faded all the way back to unchanged.
- Apple bounced but well underperformed both the S&P 500 and the NASDAQ throughout the session.
- Google jumped back to near its most recent highs with a strong bid underneath it.
- Broadcom put in a full two standard deviation move to the upside on news from yesterday.
Without Tesla, Microsoft, and Apple carrying weight, this market has a problem. Meta can fly 6.5%. Broadcom can rip. Google can bid. It does not matter if the heavyweights are broken.
The VIX is still sitting at 21. The vol futures have flattened but not normalized. I expect considerably more than the $84 of expected movement priced in for the rest of this week.
Before any geopolitical risk entered the picture, tech was already in trouble. This rally has not fixed that.
To your success,
Don Kaufman
Chief Market Strategist, TheoTRADE
The Market’s No. 1 Trading Guide, Free
This is the perfect time to make sure you’re up to speed on your trading know-how. So I want to ensure you’ve read our free Rebel’s Guide to Trading Options – it covers all the basics of trading options. Like everything we do, the course is in plain English. It’s specially geared toward beginners but all traders will get something out of it. Yours absolutely free, of course – right here…
Recent Media Appearances by TheoTrade
Jeff Bierman talks A.I. with YahooFinance LIVE
Click here to watch and read the interview >>>
Follow Us on Twitter for Free Market Updates Throughout the Day: https://twitter.com/
NEW MEDIA CHANNEL – JOIN TheoTRADE on RUMBLE
NEED HELP? LOOKING FOR MORE ADVANCED TRAINING? CALL OUR VIP CONCIERGE SUPPORT TEAM: (623) 244-5657
For live updates throughout the week join the TotalTheo® Unlimited Monthly Streaming: https://theotrade.
Get 6 Months Membership Access for FREE
Click Here to Open and Fund a NEW tastytrade Account
Follow these step by step directions:
1. To open an account with tastytrade and enjoy an additional 6 months of TheoTRADE membership, start by clicking the button below..
2. Follow the directions on that page to open a new account.
3. Fund the account with a minimum of $2,000 in the next 30 days and keep open for at least 6 months.
4. IMPORTANT: After the new account is open AND funded email support@theotrade.com so we can verify your new account. Please note it may take us up to one week to verify your account from the time you email us.
5. TheoTrade will then provide you membership access for 6 months!
Click here to get started now…
NEED HELP? LOOKING FOR MORE ADVANCED TRAINING? CALL OUR VIP CONCIERGE TEAM: (623) 244-5657
Warm regards,
Don Kaufman
Disclaimer: Neither TheoTrade or any of its officers, directors, employees, other personnel, representatives, agents or independent contractors is, in such capacities, a licensed financial adviser, registered investment adviser, registered broker-dealer or FINRA|SIPC|NFA-member firm. TheoTrade does not provide investment or financial advice or make investment recommendations. TheoTrade is not in the business of transacting trades, nor does TheoTrade agree to direct your brokerage accounts or give trading advice tailored to your particular situation. Nothing contained in our content constitutes a solicitation, recommendation, promotion, or endorsement of any particular security, other investment product, transaction or investment. Trading Futures, Options on Futures, and retail off-exchange foreign currency transactions involves substantial risk of loss and is not suitable for all investors. You should carefully consider whether trading is suitable for you in light of your circumstances, knowledge, and financial resources. You may lose all or more of your initial investment. Opinions, market data, and recommendations are subject to change at any time. Past Performance is not necessarily indicative of future results.
WARNING: If you UNSUBSCRIBE, you will be removed from ALL email lists, including any paid subscription emails. To opt out of this list only and keep other access, forward this email to support@theotrade.com and say “remove me from this particular email list.” Unsubscribe
TheoTrade
16427 N Scottsdale Rd
Suite # 410
Scottsdale, Arizona 85254
United States
1 (800) 256-8876
RJ Hamster
The market is hinting at what comes next…
Good Afternoon,
The headlines are chaotic…
War… oil shocks… market swings…
And portfolios taking hits almost daily…
But step back for a second…
Because the market may already be hinting at what comes next.
Right now…
Some of the worst-hit sectors should be collapsing.
Banks… telecom… airlines…
And yet…
A few specific stocks inside those sectors are holding their ground.
Not soaring…
Not crashing…
Just… quietly refusing to break.
That’s not normal.
And according to Marc Lichtenfeld, Chief Income Strategist at The Oxford Club and a longtime dividend investor, it’s exactly the kind of signal smart investors watch for.
In this short interview, he explains why—and reveals 3 names already showing this pattern:
- A global banking giant operating in 95 countries, with a “sticky” cash engine most competitors can’t replicate
- A telecom leader paying 5.7% income, with pricing power that tends to snap back fast when confidence returns
- And an airline with a built-in fuel advantage so unique… it actually profits differently when energy prices spike
These aren’t random picks…
They’re leaders inside struggling sectors—the kind that often move first when the tide turns.
He also shares a grounded perspective most investors need to hear right now:
Why downturns like this are normal…
Why they tend to be shorter than they feel…
And how to think clearly when everyone else is reacting emotionally.
Bridget Bennett
MarketBeat
PS: If you want to see how Marc approaches markets like this and how he builds income-focused portfolios designed to weather volatility, you can get a free look at his Wealthy Retirement strategy here.
If you like this video, check out some of our partners’ offers.
I called Tesla at $37. This is bigger. (Ad)
From Timothy Sykes: In 2020, trader Tim Bohen recommended Tesla at $37 a share – a call that returned over 1,100% at its peak. Now he says his next setup could be bigger. SpaceX has quietly filed to go public at a reported $1.75 trillion valuation. Bohen has identified one specific ticker – available for as little as $100 – that he believes positions traders ahead of what could be the largest IPO in stock market history.
Watch Tim Bohen’s full SpaceX trade breakdown before the window closes
One space stock is up 786% this year (Ad)
From TradingTips: One space stock has returned 786% over the past twelve months – posting its first profitable year, beating Q4 estimates by double digits, and growing its backlog 79% to $900 million. Our free report covers seven space stocks to watch before the SpaceX IPO in June, including a $1 billion micro-cap launching next-gen spy satellites, a defense giant with $194 billion in backlog, and the only rocket company that can compete with SpaceX directly.
Get the free report on all seven space stocks now
Hey, Have You Claimed Your Rebate Check?? (Ad)
From Angel Publishing: The U.S. has already collected $195 billion in tariff revenue this year, with projections reaching $400 billion by 2026 – drawn from over 90 countries. Investment Director Jason Williams says a portion of that revenue is being channeled into what he calls ‘Tariff Rebate Checks’ – quarterly payouts potentially worth up to $8,276. The next payout window is approaching.
See the full briefing on how to claim your position today
Trade this between 9:30 and 10:45 am EST (Ad)
From Base Camp Trading: The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you can be at your computer between 9:30 and 10:45 a.m. on most weekdays, this short-term strategy called the Retirement Trade is designed to capture repeatable morning setups.No waiting months for results. Just a focused, simple approach built to help accelerate your retirement goals.
The SpaceX filing just happened. You’ve got weeks. (Ad)
From The Oxford Club: Reuters reports Elon Musk filed secretly. Barron’s says it’s being finalized behind closed doors. CNBC just revealed 21 banks – including JPMorgan, Goldman Sachs, and Morgan Stanley – are competing for a role in what Wall Street is calling ‘Project Apex,’ a potential $1.75 trillion listing Bloomberg has dubbed the biggest of all time. Dr. Mark Skousen, Macroeconomic Strategist at The Oxford Club, says a pre-IPO ‘backdoor’ entry still exists – and nearly 15,000 investors have already accessed his free recommendation. June is the reported target date, and the window is narrowing.
Get Dr. Skousen’s free SpaceX pre-IPO recommendation before June
4 Stocks That Could Soar Under Trump’s New Tariffs (Ad)
From The Financial Newsletter: FREE Report: 4 “America First” Stocks Poised to Soar Under Trump’s New Tariffs President Trump’s second term is officially underway—and during his first 100 days are already delivering bold moves on tariffs, energy, defense, and trade.
Click here to get your free report, 4 “America First” Stocks That Could Soar Under Trump’s New Tarif
Thank you for subscribing to MarketBeat!
We empower investors to make better financial decisions by providing real-time financial information and best-in-class market research.
If you have questions or concerns about your newsletter, don’t hesitate to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place #620, Sioux Falls, South Dakota 57103. United States..
Today’s Bonus Content: Trump Just Backed Tech That Kills Nvidia’s Moat(From Eagle Publishing)
RJ Hamster
We’re excited to have you on board
Hello,
Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board.
Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox.
You’re just two quick steps away from completing your sign-up:
1. Make sure our emails go to your inbox
Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary
Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP
Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts
2. Confirm your subscription
Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter.
Confirm your subscription here.
After you confirm, feel free to download our popular free report, “7 Stocks to Buy and Hold Forever” with this link.
Thanks again for subscribing—we look forward to being part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week’s Featured Story
Down 75% From Its High, How Much Lower Can Nike Get?
By Thomas Hughes. First Published: 4/2/2026.
Key Points
- Nike is in a position to move lower, as results and guidance undermine investor confidence.
- Amid a market shift, Nike will struggle to reclaim lost market share.
- Valuation metrics suggest this stock has room to move lower in 2026.
- Special Report: Elon Musk already made me a “wealthy man”
Nike (NYSE: NKE) stumbled, and while a turnaround appears to be gaining traction, headwinds remain fierce. The recovery is taking longer than investors expected, leaving the stock vulnerable to further declines.
The primary takeaway from the fiscal Q3 2026report is that weakness will likely persist for at least another quarter — possibly longer — keeping sentiment negative and the stock under pressure.
Iran War TRUTH: What Was Revealed Behind Closed Doors (Ad)
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.Click here to find out what it is.
Analysts continue to rate Nike as a consensus Moderate Buy with a Buy-side bias. Nevertheless, sentiment and price targets have deteriorated in 2026, and the trend accelerated after the update. MarketBeat-tracked revisions include downgrades and price target cuts, suggesting a consensus rating downgradecould occur in the coming quarter alongside lower price expectations.
The chart signals are not constructive. The market gapped down and continued lower, and momentum indicators such as stochastic and the MACD are signaling a sell. The move came with significantly increased volume, which suggests this could be the start of a larger downward leg.
Optimism Erodes, Nike Analysts Cut Ratings and Price Targets
Consensus forecasts a rebound from the early-April lows, but the prevailing trend is eroding investor confidence. The low end of analyst targets points to double-digit downside, and with continued weakness expected next quarter, analysts are unlikely to establish a firm floor until after the next earnings release.
One major hurdle is loss of market share to competitors such as On Holdings (NYSE: ONON). While Nike’s revenue and earnings have contracted recently, some lines of the business still outperformed expectations. The bigger risk is that Nike no longer commands the same unchallenged position in the market as newer brands gain traction.
Institutions may provide some support, but the picture is mixed. Data show institutions bought on balance in Q1, but only marginally; they own roughly 65% of the shares outstanding. If that cohort begins to distribute, it could exert meaningful downward pressure. Short interest has risen but remains modest, under 3% of shares outstanding, so short sellers are a smaller risk for now.
Valuation is also a concern. The roughly 15% post-release decline eased some pressure, but at about 22x forward earnings Nike may no longer deserve a premium given its challenges. Is Nike in danger of defeat? Unlikely — the brand is too large and entrenched — but it is facing a significant market shift and is no longer the uncontested leader. That leaves room for On Holdings and others to capture share as they build momentum.
Capital returns have been a reason to own Nike, but that pillar faces risk too. The company is unlikely to cut or suspend its dividend, but it may slow the pace of dividend hikes. Share buybacks are down significantly year over year and could be curtailed further if the turnaround stalls and cash priorities shift.
Weak Results and Soft Guidance Undermine Nike Stock Price
Nike’s fiscal Q3 revenue beat expectations, but that outcome wasn’t surprising given the low bar analysts had set. The modest upside was more than offset by tepid growth, margin compression, and guidance that points to continued weakness.
Segment results help explain the situation. Wholesale — which Nike is refocusing on — improved by 5%, but that gain was offset by softness in direct-to-consumer (DTC). Earlier emphasis on DTC growth contributed to pressures in wholesale, and the company now faces the challenge of finding the right balance to sustain growth and margins amid intensifying competition.
Guidance was the catalyst for the sell-off. Analysts had hoped Q3 would be the trough and that Q4 would show improvement; instead, Nike’s management set guidance implying revenue could decline by about 3% at the midpoint, well below the roughly 2% increase analysts had expected. That gap between expectations and guidance is weighing heavily on the stock.
Thank you for subscribing to MarketBeat!
We empower investors to make better investment decisions by delivering real-time financial information and unbiased investment analysis.
If you need help with your account, please don’t hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. U.S.A..